B
Beatriz M. Carreno
Researcher at Washington University in St. Louis
Publications - 59
Citations - 15718
Beatriz M. Carreno is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 33, co-authored 49 publications receiving 14099 citations. Previous affiliations of Beatriz M. Carreno include MedImmune.
Papers
More filters
Journal ArticleDOI
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Gordon J. Freeman,Andrew J. Long,Yoshiko Iwai,Karen Bourque,Tatyana Chernova,Hiroyuki Nishimura,Lori Fitz,Nelly Malenkovich,Taku Okazaki,Michael C. Byrne,Heidi F. Horton,Lynette A. Fouser,Laura L. Carter,Vincent Ling,Michael R Bowman,Beatriz M. Carreno,Mary Collins,Clive Wood,Tasuku Honjo +18 more
TL;DR: It is reported here that the ligand of PD-1 (PD-L1), an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells, is a member of the B7 gene family.
Journal ArticleDOI
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman,Clive Wood,Tatyana Chernova,Divya Chaudhary,Madhuri Borde,Irene Chernova,Yoshiko Iwai,Andrew J. Long,Julia A. Brown,Raquel A. Nunes,Edward A. Greenfield,Karen Bourque,Vassiliki A. Boussiotis,Laura L. Carter,Beatriz M. Carreno,Nelly Malenkovich,Hiroyuki Nishimura,Taku Okazaki,Tasuku Honjo,Arlene H. Sharpe,Gordon J. Freeman +20 more
TL;DR: These studies show overlapping functions of PD-L1 andPD-L2 and indicate a key role for the PD- L–PD-1 pathway in regulating T cell responses.
Journal ArticleDOI
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno,Vincent Magrini,Michelle Becker-Hapak,Saghar Kaabinejadian,Jasreet Hundal,Allegra A. Petti,Amy Ly,Wen Rong Lie,William H. Hildebrand,Elaine R. Mardis,Gerald P. Linette +10 more
TL;DR: The results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Journal ArticleDOI
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette,Edward A. Stadtmauer,Marcela V. Maus,Aaron P. Rapoport,Bruce L. Levine,Lyndsey Emery,Leslie A. Litzky,Adam Bagg,Beatriz M. Carreno,Patrick J. Cimino,Gwendolyn Binder-Scholl,Dominic P. Smethurst,Andrew B. Gerry,Nick Pumphrey,Alan D. Bennett,Joanna E. Brewer,Joseph Dukes,Jane Harper,Helen K. Tayton-Martin,Bent K. Jakobsen,Namir J. Hassan,Michael Kalos,Carl H. June +22 more
TL;DR: Clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3 demonstrated that TCR-engineered T cells can have serious and not readily predictable off-target and organ-specific toxicities and highlight the need for improved methods to define the specificity of engineeredTCRs.
Journal ArticleDOI
The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses
Beatriz M. Carreno,Mary Collins +1 more
TL;DR: Understanding the pathways of integration of signals through this family of costimulatory and inhibitory receptors and their ligands is critical for activation of immune responses and tolerance will allow development of new strategies for therapeutic intervention in immune-mediated diseases.